Abstract:A 51-year-female presented to our hospital for repeated syncope. Eighteen years before, she had been diagnosed with hypertrophic obstructive cardiomyopathy and discharged after alcohol septal ablation with symptoms relieved. Family history revealed the patient's mother and her older brother had died suddenly at the age of 40 years of unidentified reason. Blood test was negative except for N-terminal pro-brain natriuretic peptide (NT-proBNP) 636 pg/mL and troponin T 35.4 ng/L. Echocardiography revealed asymmetric left ventricular hypertrophy with the interventricular septum (IVS) of 19 mm (Figure 1A) and left ventricular posterior wall (LVPW) of 12 mm, along with left atrial enlargement, normal systolic function (left ventricular ejection fraction: 57%) and Grade II diastolic dysfunction (transmitral E/A ratio 0.5). Cardiac magnetic resonance (CMR) showed multiple patchy late gadolinium enhancement (LGE) in the IVS (Figure 1B). Implantable cardioverter defibrillator was implanted for sudden cardiac death prevention. Family screening reported her asymptomatic daughter to have similar asymmetric and extreme LV hypertrophy (IVS 20 mm) with no left ventricular outflow tract obstruction on echocardiography and patchy LGE in the same area on CMR. However, the patient's younger brother, who suffered recurrent cerebral infarction with atrial fibrillation and recently admitted due to exertional shortness of breath, developed different abnormalities on echocardiography. Both atria were remarkably enlarged, exceeding his ventricles (Figure 1C). LV systolic function was preserved (left ventricular ejection fraction: 54%) while E/A ratio (>2) and E/e′ ratio (>15) was prominently increased, suggesting a typical restrictive filling pattern. Unlike the proband's, his left ventricular wall was only mildly thickened (IVS 12 mm and LVPW 12 mm) on echocardiography while CMR revealed no obvious thickening but diffuse patchy LGE in the left ventricular walls (Figure 1D). Based on these findings, his final diagnosis was restrictive cardiomyopathy. Genetic analysis of the family members identified the same mutation (c.2770G>A p.E924K) in exon 23 of sarcomeric cardiac beta-myosin heavy chain gene (MYH7) (Figure 1E,F) despite different clinical phenotypes of cardiomyopathy in the three patients. Mutations in the MYH7 gene are known to be associated with a variety of myocardial disorders. MYH7 encodes the myosin heavy chain sarcomeric β-myosin heavy chain and is a common cause of both hypertrophic and dilated cardiomyopathy.1 However, MYH7-related RCM is rarely reported. The relationship between the MYH7 mutations and clinical manifestations are complex and the mechanisms behind the genotype–phenotype correlation are not clearly understood.2 This is the first report about the MYH7 mutation of p.E924K in a same family manifested as two divergent phenotypes as HCM and RCM, which may improve our understanding on the genotype–phenotype correlation between the MYH7 mutation and RCM. The authors declare no conflict of interest.

A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated β-myosin heavy chain genes

Characteristics of the beta myosin heavy chain gene Ala26Val mutation in a Chinese family with hypertrophic cardiomyopathy.

[Advances in the Molecular Pathogenesis of Hypertrophic Cardiomyopathy].

The Novel Mitochondrial 16S Rrna 2336T>C Mutation is Associated with Hypertrophic Cardiomyopathy

A malignant phenotype of hypertrophic cardiomyopathy caused by Arg719Gln cardiac beta-myosin heavy-chain mutation in a Chinese family.

A novel mutation of the beta myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy.

Exome Sequencing Identifies a Novel MYH7 P.g407c Mutation Responsible for Familial Hypertrophic Cardiomyopathy

A MYH7 variant in a five-generation-family with hypertrophic cardiomyopathy

Genetic basis of hypertrophic cardiomyopathy in children

Mutation of Arg723Gly in Β-Myosin Heavy Chain Gene in Five Chinese Families with Hypertrophic Cardiomyopathy

Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy.

Family screening of hypertrophic cardiomyopathy in children: a case report

Myosin Heavy Chain Converter Domain Mutations Drive Early-Stage Changes in Extracellular Matrix Dynamics in Hypertrophic Cardiomyopathy

[Mutations in Beta Myosin Heavy Chain Gene: Two Mutations in Chinese with Familial Hypertrophic Cardiomyopathy and the Correlation Between the Genotype and Phenotype].

Whole-exome Sequencing Reveals MYH7 P.r671c Mutation in Three Different Phenotypes of Familial Hypertrophic Cardiomyopathy.

A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy

Novel Phenotype–genotype Correlations of Hypertrophic Cardiomyopathy Caused by Mutation in Α-Actin and Myosin-Binding Protein Genes in Three Unrelated Chinese Families

Approaching the Facts Between Genetic Mutation and Clinical Practice of Hypertrophic Cardiomyopathy

Abstract 11879: the Genetic Characteristics Based on Next Generation Sequencing in Patients with Hypertrophic Cardiomyopathy

Abstract 20016: Genetic Anticipation in Familial Hypertrophic Cardiomyopathy

Same MYH7 Gene Mutation but Different Phenotypes of Cardiomyopathy in One Family